1998;339:32
J
-8.
19.CaidahlK.Relationbetweencardiacdyspneaand left
ventricular function. A non-invasive study of 67-year–
old men [Akademisk avhandling]. Acta Med Scand
1987;suppl 719:1-62.
20. NelesenRA,DimsdaleJE,ZieglerMG.Plasmaatrial
natriuretic peptide is unstable under most storage
conditions. Circulation
J
992;86:463-6.
21. Artner-Dworzak E, Lindner H, Puschendorf B. In
vitro stability of human atrial natriuretic peptide (h–
ANP). Clin ChimActa 1991;203:235-42.
22. Tsuji T, Imagawa K, Masuda H, Haraikawa M,
ShibataK,KonoM,InouyeK,UchidaK.Stabilizationof
human brain natriuretic peptide in blood samples. Clin
Chem 1994;40:672-3.
23. ClelandJGF,WardS,DutkaD,HabibF,Impallomeni
M, Morton
IJ.
Stability of plasma concentrations of N
andC terminal atrial natriureticpeptictesat room tempera–
ture. Heart 1996;75:410-3.
24. BuckleyMG,Marcus NJ,YacoubMH, SingerDRJ.
Prolongedstabilityofbrainnatriureticpeptide: importance
fornon-invasiveassessmentofeardiacfunction inclinical
practice. Clin Sci (Colch) 1998;95(3):235-9.
25. Hall C, Aaberg L, Stokke O. In vitro stability ofN–
terminal proatrial natriuretic factor in unfrozen samples:
an important prerequisite for its use as a biochemical
parameter of atrial pressure in clinical routine [Letter].
Circulation 1995;91:911.
26. DavidsonNC,CoutieWJ, StruthersAD. N-terminal
proatrial natriureticpeptide and brain natriuretic peptide
are stable for up to 6 hours in whole blood in vitro.
Circulation 1995; 91:1276-7.
27. Murdoch DR, Byme J, Morton JJ, McDonagh TA,
RobbSD,ClementsS,Ford l,McMurrayJJV,DargieHJ.
Brainnatriureticpeptideisstable inwholeblood andcan
bemeasured using a simple rapid assay: implications for
clinical practice. Heart 1997;78:594-7.
28. Prasad K, Fredericks S, Holt DW. Measuring brain
natriuretic peptide. Lancet 1996;348:626.
29. Landahl S, Steen B, Svanborg A. Dyspnea in 70-
year-old people. ActaMed Scand 1980;207:225-30.
Klinisk Kemi
i
Norden 3, 1998
30. Eriksson H, Svärdsudd K, Larsson B et al. Risk
factors for heart failure in the general population: the
studyofmen bom in 1913.EurHeartJ 1989;10:647-56.
31. Landahl S, Svanborg A, Åstrand
K.
Heart volume
and the prevalence of certain common cardiovascular
disordersat70and75yearsofage.EurHeartJ1984;5:326-
31.
32. Wallen T. Natriuretic peptictes in the elderly.
Implications for morbidity and mortality [Akademisk
avhandling]. Göteborgs Universitet: Göteborg, 1997.
33. DavisM, Espiner E, Richards G, Billings J, Town
I,Neill A, DrennanC, RichardsM, Turner J,YandleT.
Plasma brain natriuretic peptide in assessment ofacute
dyspnoea. Lancet 1994;343:440-4.
34. Fleischer D, Espiner EA, Yandle TG, Livesey JH,
Billings J, Town I, Richards AM. Rapid assay of
plasma brain natriuretic peptide in the assessment of
acute dyspnoea. N ZealandMed J 1997;110:71-4.
35. Hall C, Rouleau JL,MoyeL, deChamplain J,Bichet
D,KleinM,SussexB,PackerM,Rouleau J,ArnoldMO,
Lamas GA, Sestier F, Gottlieb SS,Wun C-CC, Pfeffer
MA. N-terminal proatrial natriuretic factor. An indepen–
dent predietar of long-term prognosis after myocardial
infarction. Circulation 1994;89:1934-42.
36 StridsbergM, Pettersson T, Pettersson K. A two-site
delfia immunoassay formeasurementsoftheN-terminal
peptide of pro-atrial natriuretic peptide (nANP). Upsala
JMed Sci 1997;102:99-108.
37. Grantham JA, Bumett JC Jr. Natriuretic peptictes in
cardiovascular disease. A focus on congestive heart
failure. In: Samson WK, Levin ER, eds. Natriuretic
peptictes in health and disease. New Jersey: Humana
Press, 1997, pp. 309-26.)
38. Wallen T, Landahl S, Hedner T. BNP - nytt
diagnostiskt och prognostiskt hjälpmedel vid hjärtsvikt?
Corpus Medicum 1998;4(1-2):14-6.
39. Lindstedt G, Bergh CH, Caidahl K, Ekman R,
Fagerberg B, Isgaard J, Lundberg PA, Swedberg K,
Wallen T. Ökande betydelse av laboratorieunder–
sökningar vid utredning och behandling av hjärtsvikt.
Läkartidningen 199x;xx:xxxx-xxxx.
83
